Ionis Pharmaceuticals(IONS) - 2019 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the transition period from _____ to _____ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-19125 For the Quarterly Period Ended September 30, 2019 Ionis Pharmaceuticals, Inc. Form 10-Q OR (Exact name of Registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 (Mark One) Indicate by check mark whethe ...